Fernando García-Rodríguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fernando García-Rodríguez has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Adolfo Hernandez-Garduno
AHS Health Consulting, Mexico City
1 shared publication - Alfonso Gastelum-Strozzi
Instituto de Ciencias Aplicadas y Tecnología (ICAT), Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México 04510, Mexico
1 shared publication Ana V. Villarreal-Treviño
Departamento de Pediatría, Hospital Universitario “José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico
1 shared publication- Ana Victoria Villarreal-Treviño
Departamento de Pediatría, Hospital Universitario “José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey
1 shared publication Barbara Cárdenas-Del Castillo
Universidad Autonoma de Nuevo Leon, Facultad de Medicina y Hospital Universitario, "Dr. Jose Eleuterio Gonzalez", Neonatology, Department of Pediatrics, Monterrey, Mexico
1 shared publicationBeatriz Silva-Ramirez
Departamento de Inmunogenética, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social, Monterrey, México
1 shared publication
Latest Publications
- 2 October 2025
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 32 (1S) , S49-S57
Delay in Referral, Diagnosis, and Treatment in Pediatric Patients With Juvenile Systemic Lupus Erythematosus: A Systematic Review
Background/Objective: The delay in managing patients with juvenile systemic lupus erythematosus (jSLE) is one of the most important determinants impacting outcomes. Methods: We conducted a systematic review regarding the delay in referral, diagnosis, and treatment of patients with jSLE, and the barriers and facilitators related to these processes. Electronic searches were conducted in Scopus, PubMed, and Web of Science for studies published up to March 4, 2025; additionally, reports were identified through a citation search. The project followed the PRISMA guidelines, and the critical appraisal was based on the Joanna Briggs Institute Checklist (JBI). Meta-analyses, using random effects models, were conducted to estimate the delay. Results: The review included 24 papers from Europe, Asia, the Americas, and Africa. The median JBI quality score was 5 (IQR=4.75 to 6). Only one study presented a definition for the delay to diagnosis of jSLE. The estimated mean time from onset to diagnosis was 3.5 months (95% CI=2.73-4.27, I 2 =93.4%, p <0.0001). Only 3 studies reported a referral delay. Two studies indicated that all patients received therapy at diagnosis. There was no difference in the time to diagnosis between countries from the Global North and the Global South. The most common barriers identified for timely diagnosis were male sex, low anti-nuclear antibody titers, low family income, and patients presenting mild clinical manifestations. Conclusions: Currently, no consensus exists on defining the delays in referral, diagnosis, or treatment for jSLE patients. Common barriers are related to both sociodemographic and clinical factors.
- 2 October 2025
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 32 (1S) , S49-S57
Delay in Referral, Diagnosis, and Treatment in Pediatric Patients With Juvenile Systemic Lupus Erythematosus: A Systematic Review
Background/Objective: The delay in managing patients with juvenile systemic lupus erythematosus (jSLE) is one of the most important determinants impacting outcomes. Methods: We conducted a systematic review regarding the delay in referral, diagnosis, and treatment of patients with jSLE, and the barriers and facilitators related to these processes. Electronic searches were conducted in Scopus, PubMed, and Web of Science for studies published up to March 4, 2025; additionally, reports were identified through a citation search. The project followed the PRISMA guidelines, and the critical appraisal was based on the Joanna Briggs Institute Checklist (JBI). Meta-analyses, using random effects models, were conducted to estimate the delay. Results: The review included 24 papers from Europe, Asia, the Americas, and Africa. The median JBI quality score was 5 (IQR=4.75 to 6). Only one study presented a definition for the delay to diagnosis of jSLE. The estimated mean time from onset to diagnosis was 3.5 months (95% CI=2.73-4.27, I 2 =93.4%, p <0.0001). Only 3 studies reported a referral delay. Two studies indicated that all patients received therapy at diagnosis. There was no difference in the time to diagnosis between countries from the Global North and the Global South. The most common barriers identified for timely diagnosis were male sex, low anti-nuclear antibody titers, low family income, and patients presenting mild clinical manifestations. Conclusions: Currently, no consensus exists on defining the delays in referral, diagnosis, or treatment for jSLE patients. Common barriers are related to both sociodemographic and clinical factors.
- 4 November 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (12) , 3849-3853
Relationship between SLCO1B1 polymorphisms and methotrexate intolerance in Mexican children with juvenile idiopathic arthritis
Introduction The most frequent adverse events (AEs) of methotrexate (MTX) are gastrointestinal symptoms and hepatotoxicity, which can affect its adherence, leading to reduced effectiveness. The SLCO1B1 gene codes for a liver protein (OATP1B1) responsible for drug transportation. Genetic variations within the SLCO1B1 gene locus impact drug transport, leading to altered pharmacokinetic profiles, delayed MTX clearance, and increased risk of toxicity. This study aimed to determine the association between single nucleotide polymorphisms (SNPs) in the SLCO1B1 gene (rs4149056, rs2306283) with the development of AEs in patients with juvenile idiopathic arthritis (JIA) treated with MTX. Method We performed an observational retrospective study to analyze the relationship between SNPs in the SLCO1B1 gene and the development of AEs in pediatric patients treated with MTX for JIA. Results Thirty patients with JIA were included, 22 females (73.3%), with a median age of 11 years (IQR 8.3–15). The most frequent JIA subtype was rheumatoid factor-positive polyarthritis (36.7%). Twenty patients (66.7%) reported AEs. The *1B haplotype was the most frequent in this group (53.3%) and conferred a higher risk of developing AEs (OR = 3.89, 95% CI = 1.23 -12.29, p = 0.03). Conclusions Patients with the allele *1B may benefit from lower doses of MTX. SLCO1B1 genotyping is a promising technique to identify patients at higher risk of AEs during treatment with MTX, thus requiring dose optimization. Key Points • The most frequent SLCO1B1 haplotype in our population was *1B, also associated with a higher risk of developing adverse events (OR=3.89, 95% CI=1.23 -12.29, p=0.03). • SLCO1B1 genotyping is a promising tool to help identify patients at higher risk of MTX-related AEs.
- 4 November 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (12) , 3849-3853
Relationship between SLCO1B1 polymorphisms and methotrexate intolerance in Mexican children with juvenile idiopathic arthritis
Introduction The most frequent adverse events (AEs) of methotrexate (MTX) are gastrointestinal symptoms and hepatotoxicity, which can affect its adherence, leading to reduced effectiveness. The SLCO1B1 gene codes for a liver protein (OATP1B1) responsible for drug transportation. Genetic variations within the SLCO1B1 gene locus impact drug transport, leading to altered pharmacokinetic profiles, delayed MTX clearance, and increased risk of toxicity. This study aimed to determine the association between single nucleotide polymorphisms (SNPs) in the SLCO1B1 gene (rs4149056, rs2306283) with the development of AEs in patients with juvenile idiopathic arthritis (JIA) treated with MTX. Method We performed an observational retrospective study to analyze the relationship between SNPs in the SLCO1B1 gene and the development of AEs in pediatric patients treated with MTX for JIA. Results Thirty patients with JIA were included, 22 females (73.3%), with a median age of 11 years (IQR 8.3–15). The most frequent JIA subtype was rheumatoid factor-positive polyarthritis (36.7%). Twenty patients (66.7%) reported AEs. The *1B haplotype was the most frequent in this group (53.3%) and conferred a higher risk of developing AEs (OR = 3.89, 95% CI = 1.23 -12.29, p = 0.03). Conclusions Patients with the allele *1B may benefit from lower doses of MTX. SLCO1B1 genotyping is a promising technique to identify patients at higher risk of AEs during treatment with MTX, thus requiring dose optimization. Key Points • The most frequent SLCO1B1 haplotype in our population was *1B, also associated with a higher risk of developing adverse events (OR=3.89, 95% CI=1.23 -12.29, p=0.03). • SLCO1B1 genotyping is a promising tool to help identify patients at higher risk of MTX-related AEs.
- 1 September 2020
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 55 (9) , 1920-1924
Predicting the optimal depth of ultrasound-guided right internal jugular vein central venous catheters in neonates
- 1 September 2020
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 55 (9) , 1920-1924
Predicting the optimal depth of ultrasound-guided right internal jugular vein central venous catheters in neonates